Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 5/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 4/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21708260 | 0.91 | KEAP1 (0.47) | KEAP1NFE2L2KMT2ANPSR1POLB | |
| SCHEMBL21708353 | 0.90 | KEAP1 (0.46) | KEAP1NFE2L2KMT2AMEN1 | |
| SCHEMBL21708264 | 0.89 | KEAP1 (0.41) | KEAP1NFE2L2HTR6KMT2APOLB | |
| SCHEMBL21708272 | 0.89 | KEAP1 (0.42) | KEAP1NFE2L2KMT2ANPSR1POLB | |
| SCHEMBL21708329 | 0.88 | TSHR (0.38) | KEAP1NFE2L2KMT2ANPSR1POLB | |
| SCHEMBL21708293 | 0.87 | KEAP1 (0.41) | KEAP1NFE2L2HTR6KMT2ANPSR1 | |
| SCHEMBL21708221 | 0.83 | KEAP1 (0.40) | KEAP1NFE2L2PAX8HTR6CNR2 | |
| SCHEMBL21708366 | 0.83 | KEAP1 (0.40) | KEAP1NFE2L2KMT2AMEN1TSHR | |
| SCHEMBL21708297 | 0.83 | GPR119 (0.45) | KMT2AMEN1 | |
| SCHEMBL21708302 | 0.79 | CHRM1 (0.42) | KEAP1NFE2L2PAX8HTR6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210107871-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2021-04-15 | — | — | US | disclosed |
| EP-3611161-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | National University Corporation Hokkaido University (JP) | 2020-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107871-A1 | BIARYL SULFONAMIDE DERIVATIVE HAVING FILOVIRUS CELL ENTRY INHIBITION ACTIVITY | FLNA, FLNB, BRI3BP | KEAP1 3844/4885NFE2L2 3888/4885PAX8 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.